• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

急性髓系白血病靶向纳米脂质体对JAK/STAT3表达的抑制作用以增强化疗效果

Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement.

作者信息

Zuo Yao, Li Hongwen, Wang Xiaochao, Liang Yejin, Huang Caihong, Nai Guanye, Ruan Jingrong, Dong Wenzheng, Lu Xiang

机构信息

Department of Hematology & Oncology, Affiliated Hospital of Youjiang Medical University for Nationalities, Guangxi 533000, P. R. China.

Department of Hematology, The First People's Hospital of Nanning, Guangxi 530022, P. R. China.

出版信息

ACS Omega. 2024 Aug 28;9(36):37901-37909. doi: 10.1021/acsomega.4c00710. eCollection 2024 Sep 10.

DOI:10.1021/acsomega.4c00710
PMID:39281932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11391460/
Abstract

Acute myeloid leukemia (AML) is a relatively common malignant hematological disease whose development is mostly associated with abnormal activation of the JAK/STAT3 signaling pathway. Our previous study revealed that SAR317461, a novel JAK2/STAT3 inhibitor, can effectively inhibit the activation of the JAK2/STAT3 signaling pathway and has significant damaging and pro-apoptotic effects on AML cell lines. This project aims to build upon our prior research to enhance the application of SAR317461 in AML. The surface modification of liposomes with the CD34 antibody, along with the inclusion of the SAR317461 and cytarabine (a common AML chemotherapeutic agent), is observed. Due to the high expression of CD34 on the surface of AML cells, the nanoliposome could target AML cells specifically, further achieving an effective treatment for AML through the synergistic effect of JAK2/STAT3 inhibitors and chemotherapeutic agents. The implementation of this project will provide more theoretical support and ideas for the clinical application of JAK/STAT3 inhibitors in malignant tumors and for overcoming chemotherapy resistance.

摘要

急性髓系白血病（AML）是一种相对常见的恶性血液疾病，其发展大多与JAK/STAT3信号通路的异常激活有关。我们之前的研究表明，新型JAK2/STAT3抑制剂SAR317461能够有效抑制JAK2/STAT3信号通路的激活，并且对AML细胞系具有显著的破坏和促凋亡作用。本项目旨在基于我们之前的研究，加强SAR317461在AML中的应用。观察到用CD34抗体对脂质体进行表面修饰，并加入SAR317461和阿糖胞苷（一种常用的AML化疗药物）。由于AML细胞表面CD34的高表达，纳米脂质体可以特异性地靶向AML细胞，通过JAK2/STAT3抑制剂和化疗药物的协同作用进一步实现对AML的有效治疗。本项目的实施将为JAK/STAT3抑制剂在恶性肿瘤中的临床应用以及克服化疗耐药性提供更多的理论支持和思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/dc3cc29d1641/ao4c00710_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/7c05221f7a8f/ao4c00710_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/6ebc45b8369b/ao4c00710_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/1f51402de98f/ao4c00710_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/627d23114e6c/ao4c00710_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/dc3cc29d1641/ao4c00710_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/7c05221f7a8f/ao4c00710_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/6ebc45b8369b/ao4c00710_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/1f51402de98f/ao4c00710_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/627d23114e6c/ao4c00710_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/594c/11391460/dc3cc29d1641/ao4c00710_0005.jpg

相似文献

1
Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement.急性髓系白血病靶向纳米脂质体对JAK/STAT3表达的抑制作用以增强化疗效果
ACS Omega. 2024 Aug 28;9(36):37901-37909. doi: 10.1021/acsomega.4c00710. eCollection 2024 Sep 10.
2
Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.青蒿琥酯通过阻断JAK/STAT3信号通路逆转急性髓系白血病对阿糖胞苷的耐药性。
Hematology. 2023 Dec;28(1):2255802. doi: 10.1080/16078454.2023.2255802. Epub 2023 Oct 10.
3
Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.JAK2/STAT3抑制剂SAR317461对人胶质母细胞瘤肿瘤球的影响。
J Transl Med. 2015 Aug 18;13:269. doi: 10.1186/s12967-015-0627-5.
4
Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway.急性髓系白血病细胞通过激活 LDOC1 依赖的 STAT3 信号通路分泌含有 microRNA-4532 的外泌体，从而调节造血干细胞中的正常造血。
Stem Cell Res Ther. 2019 Dec 16;10(1):384. doi: 10.1186/s13287-019-1475-7.
5
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.人干细胞因子抗体[抗SCF]增强人CD34 +耐药髓系白血病细胞中的化疗细胞毒性。
Leuk Res. 2006 Mar;30(3):296-302. doi: 10.1016/j.leukres.2005.06.026. Epub 2005 Aug 19.
6
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.改变的生长因子受体介导的 JAK2 信号在人类急性髓系白血病干细胞的生长和维持中的作用。
Blood. 2014 May 1;123(18):2826-37. doi: 10.1182/blood-2013-05-505735. Epub 2014 Mar 25.
7
Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling.急性髓系白血病（AML）衍生的间充质干细胞通过 IL-6/JAK2/STAT3 信号诱导 AML 中的化疗耐药和上皮-间充质转化样程序。
Cancer Sci. 2023 Aug;114(8):3287-3300. doi: 10.1111/cas.15855. Epub 2023 Jun 4.
8
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.JAK2 V617F在初发急性髓系白血病中是一个罕见发现，但STAT3激活很常见且原因不明。
Leukemia. 2006 Jun;20(6):971-8. doi: 10.1038/sj.leu.2404206.
9
Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.粒细胞集落刺激因子和粒细胞巨噬细胞集落刺激因子相关的JAK/STAT信号转导通路蛋白在正常粒细胞生成及急性髓性白血病原始细胞中的表达
Exp Hematol. 1999 May;27(5):885-94. doi: 10.1016/s0301-472x(99)00017-x.
10
MLAA-34 knockdown shows enhanced antitumor activity via JAK2/STAT3 signaling pathway in acute monocytic leukemia.MLAA-34基因敲低通过JAK2/STAT3信号通路在急性单核细胞白血病中显示出增强的抗肿瘤活性。
J Cancer. 2020 Sep 30;11(23):6768-6781. doi: 10.7150/jca.46670. eCollection 2020.

本文引用的文献

1
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.活化的粒细胞和炎症细胞因子信号转导驱动 T 细胞淋巴瘤的进展和疾病症状。
Blood. 2023 Jun 8;141(23):2824-2840. doi: 10.1182/blood.2022015653.
2
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.青蒿琥酯通过调控 Noxa/Bim/Mcl-1/p-Chk1 轴增强 venetoclax 联合阿糖胞苷靶向 AML 细胞的作用。
Cell Death Dis. 2022 Apr 20;13(4):379. doi: 10.1038/s41419-022-04810-z.
3
Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A.
通过 SHP-2 介导的管托卡品醇 A 对 JAK/STAT3 通路的失活抑制成骨肉瘤细胞增殖。
J Adv Res. 2021 Jun 11;34:79-91. doi: 10.1016/j.jare.2021.06.004. eCollection 2021 Dec.
4
Recent advancements in liposome technology.脂质体技术的最新进展。
Adv Drug Deliv Rev. 2020;156:4-22. doi: 10.1016/j.addr.2020.06.022. Epub 2020 Jun 25.
5
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.朝着配体功能化脂质体在靶向癌症治疗中的临床转化迈进：挑战与机遇。
J Control Release. 2018 May 10;277:1-13. doi: 10.1016/j.jconrel.2018.02.040. Epub 2018 Mar 1.
6
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.JAK/STAT3 轴：实体恶性肿瘤的全面药物靶点。
Semin Cancer Biol. 2017 Aug;45:13-22. doi: 10.1016/j.semcancer.2017.06.001. Epub 2017 Jun 21.
7
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.阳离子地塞米松衍生物与 STAT3 抑制剂（WP1066）联合用于侵袭性黑色素瘤：一种重新利用 I 期临床试验药物的策略。
Mol Cell Biochem. 2017 Dec;436(1-2):119-136. doi: 10.1007/s11010-017-3084-z. Epub 2017 Jun 5.
8
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.帕西替尼与厄洛替尼对表皮生长因子受体突变阳性非小细胞肺癌中JAK2介导的耐药性的协同作用。
Exp Cell Res. 2016 Jun 10;344(2):194-200. doi: 10.1016/j.yexcr.2016.05.008. Epub 2016 May 11.
9
Molecular therapy for acute myeloid leukaemia.急性髓系白血病的分子治疗
Nat Rev Clin Oncol. 2016 May;13(5):305-18. doi: 10.1038/nrclinonc.2015.210. Epub 2015 Dec 1.
10
Targeting novel signaling pathways for resistant acute myeloid leukemia.针对难治性急性髓系白血病的新型信号通路
Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5.